If you have been reading about peptide mapping and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
where N is 100, nx is the percentage of sequences with residue x (e.g. methionine) at position i, and px corresponds to the approximate distribution of amino acid x in all positions among all sequenced proteins. The summation runs over all 20 amino acids. After ΔGistat is computed, the conservation for position i in a subalignment produced after a perturbation of amino acid distribution at j (ΔGi | δjstat) is taken. Statistical coupling energy, denoted ΔΔGi, jstat, is simply the difference between these two values. That is:
Senator Harkin complained, "One of the purposes of this center was to investigate and validate alternative approaches. Quite frankly, I must say publicly that it has fallen short. I think quite frankly that in this center and the office previously before it, most of its focus has been on disproving things rather than seeking out and approving." Members of the scientific community criticized this comment as showing Harkin did not understand the basics of scientific inquiry, which tests hypotheses, but never intentionally attempts to "validate approaches". In 2009, the NCCAM's yearly budget was increased to about $122 million. Overall NIH funding for CAM research increased to $300 million by 2009. By 2009, Americans were spending $34 billion annually on CAM. In 2012, the Journal of the American Medical Association (JAMA) published a criticism that NCCAM had funded study after study, but had "failed to prove that complementary or alternative therapies are anything more than placebos".
Altria, like other tobacco companies, has invested in science and medical companies which develop and produce medical products for conditions caused or aggravated by smoking. As of 2024, Altria's three medical subsidiaries included the following: Cronos group (maker of recreational cannabis), Lexaria Bioscience (Developer of proprietary drug delivery technology, DehydraTECH, to improve active pharmaceutical ingredients entrance into the bloodstream) and Micreos (biotech company focused on discovering and developing recombinant proteins for chronic dermatology and oncology conditions). It has also designed and marketed electronic cigarettes. Altria launched the MarkTen and Green Smoke brands. Both of these were discontinued in December 2018. The company returned to this market through the acquisition of NJOY.
== Role in nuclear waste == Neptunium accumulates in commercial household ionization-chamber smoke detectors from decay of the (typically) 0.2 microgram of americium-241 initially present as a source of ionizing radiation. With a half-life of 432 years, the americium-241 in an ionization smoke detector includes about 3% neptunium after 20 years, and about 15% after 100 years. Under oxidizing conditions, neptunium-237 is the most mobile actinide in the deep geological repository environment of the Yucca Mountain project in Nevada. This makes it and its predecessors such as americium-241 candidates of interest for destruction by nuclear transmutation. Due to its long half-life, neptunium will become the major contributor of the total radiotoxicity at Yucca Mountain in 10,000 years. As it is unclear what happens to the non-reprocessed spent fuel containment in that long time span, an extraction and transmutation of neptunium after spent fuel reprocessing could help to minimize the contamination of the environment if the nuclear waste could be mobilized after several thousand years.
Sources: en.wikipedia.org
== Quarter-finals == The draw for the quarter-finals took place on 1 March 2023. This round included one team from the fourth tier, the lowest-ranked team remaining in the competition: Grimsby Town. Grimsby were the first fourth-tier side to reach the quarter-finals since Cambridge United in 1990.
=== Biosensors === Graphene does not oxidize in air or in biological fluids, making it an attractive material for use as a biosensor. A graphene circuit can be configured as a field effect biosensor by applying biological capture molecules and blocking layers to the graphene, then controlling the voltage difference between the graphene and the liquid that includes the biological test sample. Of the various types of graphene sensors that can be made, biosensors were the first to be available for sale.
Combinatorial biology is the generation of large numbers of molecules (usually peptides, enzymes or other polypeptides in biology) with non-natural metabolic pathways. The resulting set of molecules is referred to as a library. Because traditional methods of chemical discovery and selection relied on "natural" pathways (those formed by sources found in the wild and brought into the library), creation of the requisite number of peptides for new drug discovery was impractical. New drugs needed to be built from specific combinations of proteins among the trillions of possible combinations. Synthetic avenues for peptide generation became an important venue for drug creation in the 1980s. In 1985, Houghten's most cited paper (cited 650 times, according to Scopus) published his method for the synthesis of massive numbers of peptides—enough for practical use in pharmacological work—in the Proceedings of the National Academy of Sciences. This method was referred to as the "tea-bag" method because deprotected peptides are enclosed in mesh bags and dipped quickly into liquid solutions containing activated amino acids (or other organic compounds). The peptide is thus elongated one amino acid at each step, and by careful movement of each teabag, a series of related peptides can be made. By another variation, "split and mix", tens of millions of very diverse peptides can be made, and then assayed by some technique. Very precise deconvolution of the results, or alternatively, marking the peptide beads, can correlate sequence and activity.
Despite his cynical behaviour, he gradually wins over Arun's colleagues. Complications arise when Chandramouli and his brother-in-law, Lovababu, arrive unexpectedly in San Francisco. Though Uma promises to keep the story hidden and lies that he is Arun's childhood friend, Chandramouli, who has been aware of Pallavi's past involvement with someone, secretly tries to find if she is happy with Arun. During a business trip to Santa Monica, Pallavi witnesses Arun hugging another woman, leading her to suspect him of infidelity. Meanwhile, Chandramouli learns through a phone conversation with Arun's father that Arun had no childhood friend called Uma, eventually confirming Uma and Pallavi's past relationship through Pallavi's friend Kavitha. When Pallavi confronts Arun about the woman, his evasive answers increases his suspicion, prompting her to confide in Uma. Believing Pallavi will now leave Arun, Uma is approached by a remorseful Chandramouli, who offers to marry Pallavi to him. Before acting, Uma confronts Arun and discovers that the woman is Christie, a friend from Arun's MBA days in the United States. Christie had developed unrequited feelings for Arun. After he rejected her proposal, she attempted suicide and descended into drug addiction. Guilt-ridden, Arun had been secretly visiting her to support her rehabilitation. Arun reveals to Uma that he agreed to let Uma stay in their house precisely to prevent him from suffering a similar self-destructive path. Realizing Arun's integrity and selflessness, Uma decides to step aside.
The following is a list of fentanyl analogues (sometimes referred to as fentalogs), and includes both compounds developed by pharmaceutical companies for legitimate medical use, and those which have been sold as designer drugs. The latter have been reported to national drug control agencies such as the DEA, and some to transnational agencies such as the EMCDDA and UNODC. This is not a comprehensive or exhaustive list of fentanyl analogues, as more than 1400 compounds from this family have been described in the scientific and patent literature. However, this list does include many notable compounds that have reached late-stage human clinical trials, and compounds which have been sold as designer drugs, as well as representative examples of significant structural variations reported in the scientific and patent literature. The structural variations among fentanyl analogues can impart profound pharmacological differences between each other, especially regarding potency and efficacy. In the United States, the Drug Enforcement Administration (DEA) placed the class of "Fentanyl-Related Substances" on the list of Schedule I drugs in 2018, making it illegal to manufacture, distribute, or possess fentanyl analogs, with very broad terminology being used in its scheduling. Regarding the temporary control of fentanyl-related substances, Schedule I was extended through December 31, 2024 by Public Law 117-328.
Sources: en.wikipedia.org
== Signs and symptoms == Individuals with hyperthymesia can recall extensive details of their own lives, along with public events that hold personal significance. They often describe their memories as uncontrollable associations: when presented with a date, they immediately "see" a vivid depiction of that day without conscious effort. These memories are strikingly detailed but not literal recordings of experience. In the case of Jill Price, anonymised as "AJ" in the 2006 study by Parker, Cahill and McGaugh, her recollections resembled a movie running in her mind, yet she could not remember incidental details such as what her interviewers were wearing hours earlier.Although she describes her mind like having a movie running, she is not recording her world verbatim in its totality. One day after several hours together, she was asked to close her eyes and tell what her two interviewers were wearing. She was unable to do so. Hyperthymesia differs from other forms of exceptional memory, which usually rely on mnemonic devices or rehearsal strategies. Hyperthymestic memories are overwhelmingly autobiographical, encompassing both significant and mundane events, and are encoded involuntarily and retrieved automatically. Although hyperthymesiacs may be able to recall the day of the week on which a date occurred, they are not calendrical calculators; their recall is constrained to lived experiences and thought to operate subconsciously. Hyperthymesia is not classified as a form of autism, though certain similarities exist.
==== 2100–2199 ==== Animals (Scientific Procedures) Act (Amendment) Regulations 1993 (S.I. 1993/2102) Animals (Scientific Procedures) Act(Amendment) Order 1993 (S.I. 1993/2103) Closure of Prisons (H.M. Young Offender Institution Campsfield House) Order 1993 (S.I. 1993/2104) Gas (Authorisation Application) (Amendment) Regulations 1993 (S.I. 1993/2105) Nurses, Midwives and Health Visitors (Midwives Amendment) Rules Approval Order 1993 (S.I. 1993/2106) London South Circular Trunk Road (A205)(Thurlow Park Road, Lambeth) (Prohibition of Right Turn) Order 1993 (S.I. 1993/2107) Social Security (Claims and Payments) Amendment (No. 3) Regulations 1993 (S.I. 1993/2113) Airports (Designation) (Removal and Disposal of Vehicles) (Amendment) Order 1993 (S.I. 1993/2117) Housing Benefit and Council Tax Benefit (Miscellaneous Amendments) Regulations 1993 (S.I. 1993/2118) Income-related Benefits Schemes (Miscellaneous Amendments) (No. 4) Regulations 1993 (S.I. 1993/2119) Goods Vehicles (Operators' Licences) (Temporary Use in Great Britain) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/2120) Air Navigation (Restriction of Flying) (High Security Prisons) (Amendment No. 3) Regulations 1993 (S.I. 1993/2123) Winchester–Preston Trunk Road (A34) (Newbury Bypass Detrunking) (No.2) Order 1993 (S.I. 1993/2128) Winchester–Preston Trunk Road (A34) (Newbury Bypass) Slip Roads (No.3) Order 1993 (S.I. 1993/2129) East Worcester and Severn Trent Water (Amendment of Local Enactments etc.) Order 1993 (S.I. 1993/2130) County Court Appeals (Amendment) Order 1993 (S.I.
Vitamin K is distributed differently within animals depending on its specific homologue. Vitamin K1 is mainly present in the liver, heart and pancreas, while MK-4 is better represented in the kidneys, brain and pancreas. The liver also contains longer chain homologues MK-7 to MK-13. The function of vitamin K2 in the animal cell is to add a carboxylic acid functional group to a glutamate (Glu) amino acid residue in a protein, to form a gamma-carboxyglutamate (Gla) residue. This is a somewhat uncommon posttranslational modification of the protein, which is then known as a "Gla protein". The presence of two −COOH (carboxylic acid) groups on the same carbon in the gamma-carboxyglutamate residue allows it to chelate calcium ions. The binding of calcium ions in this way very often triggers the function or binding of Gla-protein enzymes, such as the so-called vitamin K–dependent clotting factors discussed below. Within the cell, vitamin K participates in a cyclic process. The vitamin undergoes electron reduction to a reduced form called vitamin K hydroquinone (quinol), catalyzed by the enzyme vitamin K epoxide reductase (VKOR). Another enzyme then oxidizes vitamin K hydroquinone to allow carboxylation of Glu to Gla; this enzyme is called gamma-glutamyl carboxylase or the vitamin K–dependent carboxylase. The carboxylation reaction only proceeds if the carboxylase enzyme is able to oxidize vitamin K hydroquinone to vitamin K epoxide at the same time. The carboxylation and epoxidation reactions are said to be coupled. Vitamin K epoxide is then restored to vitamin K by VKOR.
Raleigh operates under a council-manager government. Raleigh City Council consists of eight members; all seats, including the Mayor's, are open for election every two years. Five of the council seats are district representatives and two seats are citywide representatives elected at-large.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.